Drugs / K-645
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07116499 | Aug → Nov 2025 | migraine disorder | Kallyope Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K-645 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07116499 ↗ |
| Route | Oral | “Single oral dose of K-645 dose level 1” NCT07116499 ↗ |